Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“11 Clinical Trials to Look Out for in 2026
From a recent Nature Medicine Year-in-Review.
As 2026 approaches, several late-phase and high-impact trials across infectious diseases, oncology, cardiovascular medicine, immunology, and regenerative science stand out for their potential to change practice.
Trials to watch:
- M72/AS01-E – A next-generation tuberculosis vaccine aiming to prevent progression to active TB.
- 3BNC117-LS + 10-1074-LS – Long-acting broadly neutralizing antibodies for sustained HIV control without daily ART.
- Loratadine – Amiodarone – Colchicine platform trial – Repurposed anti-inflammatory strategies for long COVID.
- LASSARAB – An inactivated rabies-vector vaccine designed to prevent Lassa fever.
- Ziltivekimab – Targeting IL-6-mediated inflammation to reduce cardiovascular events.
- Daraxonrasib – A next-generation RAS inhibitor combined with chemotherapy in pancreatic cancer.
- BCMA-directed CAR-T therapy – Exploring CAR-T cells beyond oncology, in myasthenia gravis.
- Gene-edited stem cells for chronic granulomatous disease – A potential functional cure for an inherited immune disorder.
- Bria-IMT – Cell-based immunotherapy combined with checkpoint inhibition in metastatic breast cancer.
- Autologous bone-marrow-derived stem cells – Investigated for neurological repair and recovery.
- Pelacarsen – Antisense therapy to lower lipoprotein(a) and reduce major cardiovascular events.
Which one of these trials are you most excited about?
Source.”
More posts featuring Amol Akhade.